Bill Anderson
Bill Anderson (William N. Anderson, born August 23, 1966) is an American chemical engineer and business executive. He began as a process engineer in European chemical plants and held management jobs at Biogen, Genentech and Roche. He became CEO of Genentech in 2017, headed Roche Pharmaceuticals from 2019 and took over as CEO of Bayer in June 2023.
Contents10 sections
Key facts
1966 and education: Texas and chemical engineering
William N. Anderson, usually known as Bill Anderson, was born on August 23, 1966. The Federation of German Industries identifies his birthplace as Ohio, TexasTexasTexas is a U.S. state in the south-central United States, with its capital at Austin and its largest city Houston. It was admitted to the Union on December 29, 1845, as the 28th state, and the 2020 census (April 1, 2020) counted 29,145,505 residents.Open the full entry. Bayer’s own biography gives the place name followed by the country. He grew up in Texas and studied chemical engineering at the University of Texas at Austin. He recalled working in chemicals after graduation and encountering biotechnology when he returned to graduate school. At MITMassachusetts Institute of TechnologyThe Massachusetts Institute of Technology (MIT) is a private research university in Cambridge, Massachusetts, United States. It received its charter from Massachusetts in 1861, admitted its first students in 1865 and moved from Boston to its present campus in 1916. As of October 2025 it had 11,816 students, and it counts 106 Nobel laureates among members of its community.Open the full entry he earned a master’s in chemical engineering and another in management at the Sloan School.[1][2][3][4][5][6]
1989–1997The Hague, Brussels and the San Francisco Bay Area
In 1989 Anderson became a research and development process engineer at Ethyl Corporation in The Hague. The following year he worked as an engineer and shift supervisor in Brussels. He moved to Raychem Corporation in the San Francisco Bay Area in 1995 to manage business development and marketing. Two years later he left specialty chemicals for biotechnology.[2][7][4]
1997–2006Business planning and neurology at Biogen
Anderson joined Biogen in Cambridge, MassachusettsMassachusettsMassachusetts (officially the Commonwealth of Massachusetts) is a state in the New England region of the northeastern United States; its capital and largest city is Boston. One of the original 13 states, it ratified the U.S. Constitution on February 6, 1788, the sixth state to do so. Its population in the 2020 census (April 1, 2020) was 7,029,917.Open the full entry, in 1997 as a business planning manager. In 1999 he moved to London as managing director for the United KingdomUnited KingdomThe United Kingdom of Great Britain and Northern Ireland is a constitutional monarchy in north-western Europe. Its four constituent countries are England, Scotland, Wales and Northern Ireland. London is its capital. The union of England and Scotland in 1707, the union with Ireland in 1801 and the establishment of the Irish Free State in 1922 shaped its present territory. The Office for National Statistics put the UK’s resident population at 69,483,900 in mid-2025.Open the full entry and Ireland. Back in Cambridge in 2001, he served as vice president for finance and business planning. In 2004 he became vice president and general manager of the neurology business.[2][7]
2006–2018Products, North American operations and the CEO role at Genentech
Anderson joined Genentech in 2006 as senior vice president for immunology and ophthalmology. He moved to its oncology business in 2010. In 2013 he went to Basel, Switzerland, as head of global product strategy and chief marketing officer at Roche Pharmaceuticals. He returned to Genentech in 2016 to lead North American operations and served as CEO in 2017 and 2018.[2][8]
2019–2022Heading Roche Pharmaceuticals in Basel
On January 1, 2019, Anderson became CEO of Roche Pharmaceuticals. Roche’s biography records that he joined the board of Chugai Pharmaceutical in Japan in 2019. It lists his service with the Biotechnology Innovation Organization in 2017 and 2018, the Pharmaceutical Research and Manufacturers of America in 2019 and 2020, and the European Federation of Pharmaceutical Industries and Associations beginning in 2021. He left Roche at the end of 2022.[2][7][3]
2023Moving from Roche to Bayer
Bayer’s supervisory board announced Anderson’s appointment on February 8. He joined its board of management on April 1 and succeeded Werner Baumann as chairman and group CEO on June 1. His responsibilities extended beyond pharmaceuticals to consumer health and crop science. Bayer credited him with helping develop and launch 25 new medicines over his earlier career. Anderson is married and has three children, whom Bayer described as adults in 2025. His career had taken him through the United StatesUnited StatesThe United States is a federal country in North America made up of 50 states, the District of Columbia as the seat of government, and territories such as Puerto Rico and Guam; its capital is Washington, D.C. The Continental Congress adopted the Declaration of Independence on July 4, 1776. The 2020 census (April 1, 2020) counted a resident population of 331,449,281, and the 435 seats of the House of Representatives are apportioned among the states on the basis of the census.Open the full entry, Britain, Belgium, the Netherlands and Switzerland before he moved to Germany.[3][9][2][10]
2025Management cuts and a renewed contract
Anderson described Bayer’s organizational overhaul to shareholders as Dynamic Shared Ownership. At the 2025 annual meeting he said the company had about 10,000 fewer positions, had cut managerial positions by about half and had placed 90 percent of the organization within six or seven reporting layers.[11]
On July 16 the supervisory board announced a unanimous decision to extend his contract from its original expiry on March 31, 2026, to March 31, 2029. Bayer put the overall reduction at about 11,000 positions in the July announcement. Its annual report also listed strengthening the pharmaceutical pipeline, dealing with litigation, reducing debt and improving crop science profitability among its priorities.[9][12]
By August, the trade publication Fierce Pharma calculated from Bayer’s figures that more than 12,000 positions had gone during his tenure.[13]
February 2026Discussing company organization with Brian Halligan
On February 12, Sequoia CapitalSequoia CapitalSequoia Capital is a venture capital firm founded by Don Valentine in 1972, investing from the seed stage through the growth stage. Its historical investments include Apple, Cisco, Google, YouTube, Airbnb, and Stripe; in 2021 it introduced the Sequoia Capital Fund structure, which can continue to hold public securities, and in 2023 its regional businesses became independent brands and partnerships.Open the full entry released Brian HalliganBrian HalliganHubSpot co-founder, founder coach and investor.Open the full entry’s interview with Anderson. At 03:06–03:25, Anderson explains why he sees bureaucracy recur across large organizations facing otherwise different problems. Later in the conversation he describes how reducing Bayer’s reporting layers changed the way managers coached teams and how operating teams obtained resources.[14][15]
Related Organizations, Websites, and Public Accounts
Ethyl Corporation (process engineer and shift supervisor): Official website: https://www.ethyl.com/ (opens in a new window)[2][16]
Raychem Corporation (former business development and marketing manager): Career record: https://assets.roche.com/f/176343/88355d9def/875087.pdf (opens in a new window)[2][7]
Biogen (former general manager of the neurology business): Official website: https://www.biogen.com/ (opens in a new window)[2][17]
Genentech (former CEO): Official website: https://www.gene.com/ (opens in a new window)[8][18]
Roche Pharmaceuticals (former CEO): Official website: https://www.roche.com/ (opens in a new window)[2][19]
Biotechnology Innovation Organization (2017–2018): Official website: https://www.bio.org/ (opens in a new window)[2][20]
Chugai Pharmaceutical (former board member): Official website: https://www.chugai-pharm.co.jp/english/ (opens in a new window)[2][21]
Pharmaceutical Research and Manufacturers of America (2019–2020): Official website: https://phrma.org/ (opens in a new window)[2][22]
European Federation of Pharmaceutical Industries and Associations (from 2021): Official website: https://www.efpia.eu/ (opens in a new window)[2][23]
Bayer (chairman of the board of management and CEO): Official website: https://www.bayer.com/ (opens in a new window)[1][24]
LinkedInLinkedInLinkedIn is a social networking platform for professionals. It was founded in 2002 by Reid Hoffman and others, launched in 2003, and listed on the New York Stock Exchange in 2011; after Microsoft acquired it for approximately $26.2 billion in 2016, it became a wholly owned Microsoft subsidiary. Its revenue comes from membership subscriptions, advertising, and recruitment solutions.Open the full entry: https://www.linkedin.com/in/servinglifescience (opens in a new window)[1]
Sources24 sources
- Bill Anderson, chair of the Board of Management (opens in a new window)bayer.com↑
- William N. (Bill) Anderson, former members of the executive committee (opens in a new window)roche.com↑
- Bill Anderson to become CEO of Bayer AG (opens in a new window)bayer.com↑
- Tools and Weapons with Brad Smith: Bill Anderson (opens in a new window)tools-and-weapons-with-brad-smith.simplecast.com↑
- Bill Anderson, CEO Bayer AG, TDI speaker (opens in a new window)bdi.eu↑
- Board of Management, Bayer Annual Report 2025 (opens in a new window)reports.bayer.com↑
- William N. (Bill) Anderson: curriculum vitae (opens in a new window)assets.roche.com↑
- Genentech Announces Bill Anderson as Chief Executive Officer (opens in a new window)gene.com↑
- Supervisory Board of Bayer AG extends contract of CEO Bill Anderson (opens in a new window)bayer.com↑
- A conversation with Bill Anderson (opens in a new window)economicclub.org↑
- Address by Bill Anderson to the 2025 Annual Stockholders’ Meeting (opens in a new window)bayer.com↑
- Report of the Supervisory Board (opens in a new window)reports.bayer.com↑
- Bayer has laid off over 12K during Bill Anderson’s tenure as CEO (opens in a new window)fiercepharma.com↑
- Bayer’s Bill Anderson: Turning a 168 Year-Old Tanker Like a Speedboat (opens in a new window)youtube.com↑
- Bayer’s Bill Anderson: Turning a 168 Year-Old Tanker Like a Speedboat (opens in a new window)sequoiacap.com↑
- Ethyl Corporation (process engineer and shift supervisor) (opens in a new window)ethyl.com↑
- Biogen (former general manager of the neurology business) (opens in a new window)biogen.com↑
- Genentech (opens in a new window)gene.com↑
- Roche (opens in a new window)roche.com↑
- Biotechnology Innovation Organization (2017–2018) (opens in a new window)bio.org↑
- Chugai Pharmaceutical (former board member) (opens in a new window)chugai-pharm.co.jp↑
- Pharmaceutical Research and Manufacturers of America (2019–2020) (opens in a new window)phrma.org↑
- European Federation of Pharmaceutical Industries and Associations (from 2021) (opens in a new window)efpia.eu↑
- Bayer (chairman of the board of management and CEO) (opens in a new window)bayer.com↑